Acumen Pharmaceuticals
ABOS
ABOS
67 hedge funds and large institutions have $148M invested in Acumen Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
18% less capital invested
Capital invested by funds: $179M → $148M (-$31.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
82% less call options, than puts
Call options by funds: $810K | Put options by funds: $4.57M
Holders
67
Holding in Top 10
1
Calls
$810K
Puts
$4.57M
Top Buyers
| 1 | +$2.26M | |
| 2 | +$2M | |
| 3 | +$1.24M | |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$948K |
| 5 |
Man Group
London,
United Kingdom
|
+$555K |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$9.16M | |
| 3 | -$4.46M | |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.97M |